TRENDS AND MARKET OUTLOOK REPORTS
Designing for Recruitment and Retention in Rare Disease Studies
This report takes a deep dive into two areas impacting the success of these studies: recruitment and retention. Given the importance of each rare disease patient, these activities are time-intensive and resource-heavy.
Pharmacovigilance Market Dynamics and Service Provider Benchmarking (2nd edition)
ISR surveyed 100 decision-makers in the pharmacovigilance space to get insight on their experience regarding how their companies’ pharmacovigilance activities are split between processes, how much of their work is outsourced, and both in-house and outsourced personnel locations.
Central IRB Market Dynamics and Benchmarking
For this report, ISR surveyed 111 respondents regarding their insights on topics such as Central IRB selection, outsourcing trends, use, and perceptions of Central IRBs. Furthermore, recent users of 18 Central IRBs rated how well performance compared against their expectations on 21 attributes across four categories (Organization Factors, Capabilities, Submission and Review, and Study Management).
Site Start Up: Best Practices For Success
This report includes verbatim insights into the practices that create clinical site start up efficiency, the causes of inefficiency, and new practices being undertaken in an effort to improve efficiency. To get multiple perspectives on the site start up process, ISR surveyed people with site start up responsibilities at sponsors and CROs as well as people working at clinical sites, such as clinical investigators and study coordinators.
Phase I Study Trends and Market Outlook (2020-2024)
A Study Trends and Market Outlook report aims at providing our readers with a high-level view of the clinical development space. The data for this market research report comes from 137 Phase I decision-makers who were surveyed to share their insights.
Phase II/III Study Trends and Market Outlook (2018-2022)
This market research report will provide readers with a high-level view of the clinical development space. 139 Phase II/III decision-makers were surveyed to share their insights into where the Phase II/III market is now and where it’s expected to head over the next four years.
Late Phase Study Trends and Market Outlook (2018-2022)
The goal of this market research report is to provide readers with a high-level view of the clinical development space. 115 Late Phase decision-makers were surveyed to share their insights into where the Late Phase market is now and where it’s expected to head over the next four years.
CRO Market Size Projections: 2019-2024
This report gives quantitative insight into the perpetual question: “What is the size of the CRO market?” The data provide a thorough, rational perspective for clinical development services segmented by phase, geography, and service line.
CRA Salary Analysis and Work Environment
Ask any HR manager working at a CRO or sponsor organization and they will tell you there is a war for talent when it comes to hiring and retaining high-quality CRAs. ISR decided to take a deep look at not only CRA salaries, but also signing bonuses, retention bonuses, raises, and turnover with the aim of benchmarking some industry trends. We collected data from 227 CRAs from various organizations and...
Clinical Development Outsourcing Models (3rd Edition)
This market research report takes a look at user experiences with seven different clinical development outsourcing models.
Central Lab Market Dynamics and Outsourcing Performance (2019-2022)
This report will help both study sponsors and providers answer a number of questions relevant to selecting and evaluating central lab service providers. For the purpose of this report, “central lab” is defined as a vendor that supplies specimen collection kits, logistics services, safety alerts, and a wide variety of laboratory testing services as well as providing lab reports to investigators.
Clinical Manufacturing Market Dynamics and Service Provider Benchmarking
This report provides an overview of the current market dynamics in the clinical manufacturing space as well as an outlook of what our survey respondents predict the marketplace will look like in 2022.
CRO QUALITY BENCHMARKING
CRO Quality Benchmarking – Phase I Service Providers (12th Edition)
The goal of this market research report is to provide detailed information to aid in making informed decisions when outsourcing Phase I work. You can purchase a single-user license for individual use, a site-wide license giving access to the report for all employees within a single site/office location, or an enterprise-wide license giving access...
CRO Quality Benchmarking – Phase II/III Service Providers: A Look at Small and Emerging Biopharma (2020)
This research will help small and emerging biopharma companies make more informed CRO selection decisions. These findings will also help CROs optimize operational and marketing strategies to better accommodate this segment.
CRO Quality Benchmarking – Phase IV Service Providers (12th Edition)
The goal of this market research report is to provide detailed information to aid in making informed decisions when outsourcing Phase IV work. You can purchase a single-user license for individual use, a site-wide license giving access to the report for all employees within a single site/office location, or an enterprise-wide license giving access...
Bioanalytical Labs Market Dynamics and Service Provider Performance
Sponsors can use this report to evaluate their lab selection process. Bioanalytical labs can use it to learn how their company performs against competitors. Topics covered include lab selection and perceptions, lab performance, and lab service quality profiles.
eTMF Market and Service Provider Dynamics (2nd edition)
Study sponsors and CROs can use this report for insight into user experience/satisfaction with leading eTMF software providers to inform their vendor selection process, and eTMF providers can use it to better understand their own strengths and weaknesses - and those of their competitors.
mHealth In Clinical Trials: Current Status/Future Projections
For this study, Industry Standard Research (ISR) collected both qualitative and quantitative data. Qualitative telephone interviews were used to gain insight into mHealth expert viewpoints, while a quantitative, internet-based survey was used to collect hard data on familiarity with mHealth, anticipated implementation, and usage rates in recent or soon-to-be conducted clinical trials.
eCOA/ePRO Market Dynamics And Service Provider Performance (4th Edition)
This market report examines the industry perception of the eCOA/ePRO market based on data collected on nearly 200 service provider encounters with 18 eCOA/ePRO systems.
IRT Market Dynamics and Service Provider Benchmarking (3rd edition)
This market research report covers the state of the IRT and its apparent transition from standalone point products to more fully integrated systems that use and feed data into other eClinical systems such as EDC systems, CTMS, and eCOA systems, in addition to managing randomization and drug supply functions.
EDC Market Dynamics and Service Provider Performance (4th Edition)
This market research report examines the industry perception of the EDC market based on the responses of 132 industry professionals experienced with these systems. ISR has asked respondents how their respective companies handle the decisions associated with outsourcing these systems as well as how they would prefer the outsourcing be...
CTMS Market Dynamics and Service Provider Benchmarking (2nd Edition)
For this report, ISR surveyed 110 qualified CTMS decision-makers regarding their insights on topics such as CTMS selection drivers, outsourcing trends, use, and perceptions of providers. Respondents also shared general improvements they would like to see in the next generation of CTMS software and conveyed provider-specific...
Risk-Based Monitoring: Improving the Clinical Trial Site Experience
Technology forges a world where human connection is no longer inhibited by distance. Barriers are broken and replaced with virtual bridges that create unprecedented potential for an interconnected present and future. And no doubt the areas most affected by this technological nexus are ones dominated by human synergy. An area at...
DEPARTMENT MODELS AND STRUCTURES
Safety and Pharmacovigilance: Department Models and Structures
ISR conducted 11 in-depth interviews with tenured post-marketing safety and pharmacovigilance professionals from leading biotechnology and pharmaceutical companies in North America and Europe.
Managed Markets: Department Models and Structures
For this report, ISR conducted interviews with a cross-section of executive, director, and managerial level MM professionals from large, mid-size, and small pharmaceutical and biotech companies to gain a better understanding of managed markets departments, how they work, and the challenges they face.
Benchmarking The Pharma Industry’s Medical Science Liaison (MSL) Function
This market research report has been designed to be used as a benchmarking tool for companies to compare their Medical Science Liaison functions to those of other pharmaceutical and biotech organizations. You can purchase a single-user license for individual use, a site-wide license giving access to the report for all employees within...
Clinical Market Research Reports
Industry Standard Research – ISR Reports – is a full-service clinical market research company operating exclusively in the pharmaceutical and pharmaceutical services industry and a sister company of Clinical Leader. Their syndicated and custom market research capabilities enable their customers to make smarter, more informed business decisions. You’ll find links to their clinical trial market syndicated research reports below.
ISR's clinical market research reports are produced using direct feedback from decision-makers, which enables ISR to provide data on topics that, until now, were only attainable through custom research. With rigorous screening criteria and methodologies that include surveys, in-depth phone interviews, and focus groups, ISR gathers actionable information that is immediately applicable to their customers. Each report is available for to purchase online and you may also download free preview files. If you have any questions, please feel free to email info@ISRreports.com.
How To Improve eCOA/ePRO Software Systems
In Q3, 2020, ISR asked 118 respondents involved in clinical trials what eCOA/ePRO software systems needed to improve upon. Improve integration (with EDC, other systems & devices) topped the list, capturing 28% of respondent’s votes. Followed by More user-friendly (22%) and System design (flexibility, robustness, etc.) (16%) rounding out the top three.
Technology In Clinical Trials: Differences By Company Size
When looking at industrywide trends, it’s helpful to remember that large sponsors have more resources to help them pursue new technology initiatives. With that in mind, we took a look at where large vs. nonlarge sponsors differ in terms of openness to emerging trends in clinical development. The largest differences are highlighted both in the tables below and their associated graphs.
Why Phase II/III Service Providers Lose Bids
In Q2, 2020, ISR asked 146 respondents involved in outsourcing Phase II/III services what is the main reason a CRO may lose bids for Phase II/III work. High cost topped the list, capturing 37% of respondents’ votes. Followed by Lack of therapeutic experience (19%) and Lack of understanding of the trial outcomes (12%).
Rare Disease Studies: A Comfortable Patient Is A Retained Patient
What is comfort anyway? Being home. Your own bed. Your mom’s homemade anything. In rare disease studies, those things are suspended. Get through the trial and then you can seek comfort. But does it have to be this way?
Patient Recruitment Challenges In Rare Disease Studies
In Q2, 2020, ISR asked 125 respondents involved in patient recruitment and retention activities for rare disease studies about challenges they face while recruiting patients. The data below show the most challenging issue reported by respondents in finding patients for their recent rare disease studies was Multiple sites with access to only a few patients (42%). Followed by Multiple entities pursuing same small pool of patients (19%) and Rigid inclusion/exclusion criteria leading to high screenout rate (15%).
CEO KEVIN OLSON INTRODUCES YOU TO INDUSTRY STANDARD RESEARCH
ISR understands that you’re looking for confidence in your market research. With ISR, you’ll consistently receive:
- Focused Domain Expertise — We’ve operated in pharmaceuticals for over 15 years and because it’s our sole focus, our domain expertise brings value to the work that “generalist” researchers can’t deliver.
- Genuine Research Expertise — Our market research experience has developed over 20 years in many dynamic industries. We capture appropriate sample sizes, given the research objectives, and we use appropriately sophisticated statistics to uncover everything that’s real and to give you confidence in your decisions. Read our Six Questions to Ask About Your Market Research to learn more about why our industry expertise sets us apart.
- Transparency — If you’re like many, you’ve been disappointed more than once by research providers who fail to live up to their promises, providing you with their “professional judgment” in place of sound data; and suspect contacts instead of real decision-makers. We deliver the beliefs, attitudes, and intentions of people who matter – and we’ll prove it by showing you the titles of your respondents.
For additional questions about any of ISR’s reports or custom research services, please contact us at info@ISRreports.com.